Business Context and Reporting Period
This Form 8-K was filed by Pavmed Inc. on February 17, 2023, reporting events occurring on February 13 and February 14, 2023. The filing addresses the termination of a material definitive agreement involving a majority-owned subsidiary, Lucid Diagnostics Inc., and the settlement of a legal dispute with EF Hutton and Benchmark Investments, LLC.
Key Financial Metrics and Material Changes
Termination of Management Services Agreement
- Event: Lucid Diagnostics and its subsidiary LucidDx Labs terminated a Management Services Agreement (MSA) with ResearchDx, Inc. (RDx) effective February 10, 2023.
- Financial Impact: The termination reduced remaining earnout payments and management fees from $3,450,000 to $725,000.
- Net Savings: The company realized a net savings of $2,725,000.
- Payment Terms: The remaining $725,000 obligation will be satisfied via the issuance of 553,436 shares of Lucid Diagnostics common stock by February 25, 2023. No cash payments are required.
Legal Settlement
- Event: Pavmed Inc. entered into a settlement agreement with EF Hutton and Benchmark Investments regarding claims that certain financings in late 2020 and early 2021 violated an engagement letter.
- Financial Impact: The Company agreed to pay $450,000 in full and final satisfaction of all claims.
Note: This filing does not provide consolidated revenue, profit, cash flow, margin, debt, or liquidity metrics for the reporting period.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, updated financial outlook, or management commentary regarding future operational performance. The primary risks disclosed relate to the resolution of the legal dispute with Benchmark Investments, which has been settled, and the restructuring of obligations with RDx, which has been finalized to reduce future liabilities.
Investor Verification Checklist
- Verify the issuance of 553,436 shares of Lucid Diagnostics common stock to satisfy the $725,000 obligation to RDx.
- Confirm the $450,000 cash payment to Benchmark Investments has been executed.
- Review the Current Report on Form 8-K filed by Lucid Diagnostics on February 17, 2023, for detailed terms of the Termination Agreement.
- Assess the impact of the share issuance on the capital structure of Lucid Diagnostics.